23% Weight Loss! Will an Amylin Beat Retatrutide? EASD 2026

Could a new weight loss drug outperform retatrutide and Zepbound? New research presented at EASD 2026 reveals an entirely different approach to treating obesity, with one experimental combination delivering 23.3% weight loss in just 48 weeks, even in people with type 2 diabetes. In Episode 2 of The Downsized's 10-part series covering the biggest obesity research from the European Association for the Study of Diabetes (EASD) in Milan, Christopher Durham explores amylin, a hormone that could reshape the future of obesity treatment. Eli Lilly, Novo Nordisk, Zealand Pharma, and Roche are developing a new generation of medications that either target amylin independently or combine it with GLP-1 treatments to improve weight loss and metabolic health. Christopher breaks down the actual clinical trial results, including the impressive numbers, troubling side effects, and important questions that remain unanswered. In this episode: EloraTZP: Eli Lilly's experimental combination of eloralintide and tirzepatide produced 23.3% weight loss in 48 weeks. Could it eventually outperform retatrutide? Retatrutide vs. EloraTZP: How the results compare and why significantly higher treatment discontinuation rates matter. Petrelintide: Zealand Pharma and Roche's GLP-1-free amylin medication produced up to 10.7% weight loss with relatively low rates of gastrointestinal-related discontinuation. Zenagamtide (Amycretin): Novo Nordisk's dual GLP-1 and amylin medication produced 14.6% weight loss in 36 weeks in people with type 2 diabetes. CagriSema: Novo Nordisk's combination of cagrilintide and semaglutide has already been submitted to the FDA and could become the first of this new generation to reach patients. The future of obesity treatment: Could combining different hormonal pathways eventually allow doctors to personalize treatment with better results and fewer side effects? The research suggests that the future of obesity medicine may extend well beyond today's GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound. But greater weight loss does not automatically mean a better medication, particularly when side effects make treatment difficult to continue. Christopher and Laraine have personally lost more than 150 lbs using tirzepatide and remain on treatment. Through more than 2,000 videos, interviews with physicians and researchers, and conversations with hundreds of patients, The Downsized explores the science, news, and everyday realities of treating obesity as a chronic disease. COMING NEXT: Episode 3 examines GLP-1 medications and muscle loss, including Regeneron's experimental drug trevogrumab and the COURAGE clinical trial presented at EASD 2026. +++++++++++++++++++++++++++++++++++++++ Start your weight loss journey today! We use Mochi Health: https://app.joinmochi.com/eligibility... Use Laraine’s code for $40 off: QIYGO8. SHOP OUR AMAZON STORE: https://a.co/d/0gGe1MYq BOOK THE DOWNSIZED AT SEA CRUISE 2027: https://thedownsized.org/downsized-at... GET YOUR DOWNSIZED LIVE! ON TOUR TICKETS: https://thedownsized.org/meet-ups/ DOWNSIZED WEBSITE: https://thedownsized.org/ JOIN CLUB DOWNSIZED: https://www.youtube.com/@thedownsized... FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ +++++++++++++++++++++++++++++++++++++++ 00:00 New Amylin Weight Loss Drugs 2026 00:14 EASD 2026 Obesity Research Explained 01:03 What Is Amylin? How Amylin Weight Loss Drugs Work 02:27 Petrelintide Weight Loss Results: ZUPREME-1 Trial 04:15 Petrelintide Side Effects: Nausea, Vomiting, Hair Loss 05:48 Petrelintide for Type 2 Diabetes: ZUPREME-2 Results 06:23 What Is EloraTZP? Eloralintide Plus Tirzepatide 07:22 EloraTZP Weight Loss Results vs Tirzepatide 09:45 EloraTZP vs Retatrutide: Which Is Better? 11:12 Zenagamtide Amycretin Results: Novo Nordisk 12:14 CagriSema FDA Approval and Weight Loss Results 13:15 When Will Amylin Drugs Be FDA Approved? 14:34 Amylin vs GLP-1: A New Pathway for Weight Loss 16:58 GLP-1 Muscle Loss: Next Episode